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Drug rash with eosinophilia and systemic symptoms (DRESS) is a rare, severe adverse drug event that
appears with a generalized rash, fevers, and dysfunction of 1 or more organ systems. We describe 2
patients (1 adult and 1 pediatric) seen in the emergency department with DRESS, and review the
clinical presentations, potential complications, and management of DRESS. Although rare, it can be
associated with significant morbidity, including liver failure and death, and should be considered in the
differential diagnosis of patients with diffuse rash and systemic symptoms. [West J Emerg Med.
2011;12(4):559–562.]
INTRODUCTION
Drug rash with eosinophilia and systemic symptoms
(DRESS) syndrome is a life-threatening adverse drug reaction
that is distinct from other drug-related reactions. Patients with
DRESS present with generalized rash, fever and internal organ
involvement weeks to months after initiation of several known
medications. Characteristic laboratory ﬁndings include
eosinophilia and/or atypical lymphocytes, in addition to
evidence of organ dysfunction.
1,2 Prompt recognition of this
disorder is important because the mortality is 10%, but can be
up to 40% if organ failure is present.
3
Although DRESS is well described in the dermatology
literature, no case reports have been published in emergency
medicine literature. Given the potential morbidity, wide
differential diagnoses, and relatively simple treatment, it is
important for emergency physicians to consider this entity in
patients with severe rashes. In this case report, we present an
adult and a pediatric emergency department (ED) patient with
DRESS, and review the presentation, potential complications,
and management of DRESS.
CASE ONE
A 27-year-old man appeared in the ED complaining of a
whole-body rash, pruritis, and fevers. The patient had 2 recent
admissions to the hospital. Six weeks earlier, he was assaulted
and sustained a skull fracture with a subdural hematoma that
was managed surgically. At that time, he was started on
phenytoin for seizure prophylaxis and discharged
approximately 2 weeks later with oral phenytoin. Two weeks
after discharge, the patient developed facial and eye swelling
and was readmitted for a possible postoperative infection. He
was empirically treated with ﬂagyl, vancomycin, and
ceftazidine. While hospitalized, the patient developed a new
rash with high fevers, and dermatology was consulted.
Dermatology was primarily concerned about a drug allergy or
DRESS (most likely due to dilantin). Because the patient had
no laboratory abnormalities or other signs of end-organ
damage, he was treated conservatively. All medications were
stopped, and he was discharged home a week later on
acetaminophen, clindamycin lotion, hydroxyzine, cetirizine,
and triamcinolone cream.
The patient returned to the ED 7 days later with persistent
rash, itching, and fevers. He reported that for the previous
several weeks, he had been having fevers (to 1038F),
arthralgias, and a skin eruption. On physical examination, the
patient’s vital signs were a heart rate of 78 beats per minute,
blood pressure of 98/57 mm Hg, respiratory rate of 20 breaths
per minute, and pulse-oximetry of 98% on room air. He was
alert and oriented and in no apparent distress. He had no
meningismus. Lungs were clear to auscultation. Heart
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Neurologic examination was normal. His skin had a 2- to 8-mm
erythematous maculopapular eruption, most prominent on
anterior chest, back, and extremities; there were no bullae, and
no mucous membrane or genital involvement. The patient’s
laboratory results were signiﬁcant for leukocytosis with
eosinophilia and atypical lymphocytes, as well as a
transaminitis (Table).
Dermatology was consulted and was primarily concerned
about DRESS, given his diffuse rash, persistent fevers, and
laboratory abnormalities. The patient was admitted to the
hospital to monitor for the development of worsening organ
dysfunction, toxic epidermal necrolysis, and to initiate oral
prednisone, calcium, and vitamin D. An electrocardiogram,
echocardiogram, and ultrasound of the liver were performed as
an inpatient and were all within normal limits.
The patient’s skin symptoms and laboratory abnormalities
started improving on the second day of hospitalization. He was
discharged home after 3 days with a 6-week oral prednisone
taper. In consultation with neurosurgery, as well as allergy and
immunology specialists, antiepileptic medications were held.
On discharge, the patient’s rash and pruritis were signiﬁcantly
improved, and he has had no additional complications or
subsequent hospitalizations for related issues.
CASE TWO
A 10-year-old girl appeared in the pediatric ED with a 1-
week history of rash and fevers. Her mother reported that 7
days before presentation, she noted the onset of a pink rash over
her daughter’s cheeks, which had subsequently spread over her
arms, legs, trunk, and back. Initially, the rash consisted of ‘‘pink
raised bumps,’’ but during the previous 2 days had become
conﬂuent over extremities and trunk. She also had facial and lip
swelling. The rash had been accompanied by fever (measured at
1038F), fatigue, and lower extremity arthralgia. The child’s
medical history was signiﬁcant for bipolar disorder, for which
she had been taking divalproex (Depakote) and
methylphenidate for 3 years. Eleven days before the onset of
Table. Emergency department laboratory results.
Case 1 (adult) Case 2 (child) Normal range
Hematology
White blood cell count 13.3 3.1 5.0–14.0 3 1,000/lL
Hemoglobin 13.6 13.0 11.0–15.0 g/dL
Hematocrit 39.6 37.4 35.0–43.0%
Platelet count 310 144 150–350 3 1,000/lL
Neutrophils (%) 66 46 35–71%
Lymphocytes (%) 19 44 20–56%
Monocytes (%) 8 9 2–15%
Eosinophils (%) 18 ,1 0–5%
Peripheral smear Few atypical
lymphocytes
Microcytosis, elliptocytes, giant platelets,
and a few atypical lymphocytes
Prothrombin time 13.6 16.2 9.7–12.1 seconds
Partial thromboplastin time 28.4 31.1 22–35 seconds
International normalized ratio 1.30 1.57 0.80–1.20
Chemistry
Glucose 91 83 70–100 mg/dL
Blood urea nitrogen 9 25 8–18 mg/dL
Creatinine 0.7 0.7 0.5–1.2 mg/dL
CO2 25.8 19.7 22.0–30.0 mmol/L
Chloride 101 99 96–106 mmol/L
Sodium 139 133 135–145 mmol/L
Potassium 3.6 4.4 3.5–5.0 mmol/L
Aspartate transaminase 62 8,120 0–59 U/L
Alanine transaminase 296 4,790 0–34 U/L
Alkaline phosphatase 227 193 50–480 U/L
Direct bilirubin 0.19 0.41 ,0.20 mg/dL
Total bilirubin 0.52 0.95 ,1.20 mg/dL
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control of bipolar symptoms.
The child’s physical examination was remarkable for a
fever of 104.58F, heart rate of 117 beats per minute, blood
pressure of 104/50 mm Hg, respiratory rate of 20 breaths per
minute, and oxygenation of 100% on room air. She was awake
and alert with no acute distress, but appeared fatigued and in
mild discomfort. Her skin examination was signiﬁcant for pink,
edematous, thin plaques with breaking up of conﬂuent
erythema into scattered thin pink papules over elbows, feet, and
the perioral and periorbital regions. She had facial swelling
with perioral and periorbital sparing. No mucous membrane,
scleral, or genital involvement was noted. She exhibited no
meningismus and had a normal heart, lung, and abdominal
examination. A mildly enlarged lymph node was palpated in
her left axilla. The patient’s laboratory results (Table) were
signiﬁcant for transaminitis, elevated prothrombin time and
international normalized ratio, decreased white blood cells, and
atypical lymphocytes on peripheral smear (no eosinophilia was
noted).
The main differential diagnoses included DRESS, serum
sickness, Kawasaki disease, and sources of transaminitis, such
as autoimmune hepatitis or viral infection. Dermatology was
consulted in the ED. The patient’s skin examination,
transaminitis and recent initiation of lamotragine made DRESS
the most likely diagnosis. Because the patient was nontoxic
with no localizing signs of infection, she was not given empiric
antibiotics in the ED (although blood and urine cultures were
drawn, which later came back negative).
The patient was admitted to the hospital for initiation of
oral prednisone (1 mg/kg) and monitoring for worsening liver
function and development of mucous membrane involvement.
Inpatient echocardiography and liver ultrasound were
unremarkable. One day after admission, the patient’s
transaminitis was not improving; she was transferred to the
pediatric intensive care unit for closer monitoring and initiation
of intravenous N-acetylcysteine (NAC).
The patient’s liver-function tests started to improve on
hospital day 4, and she was discharged on day 8. Throughout
her hospitalization, the patient did not receive any standing
psychiatric medications. Although she did have an
exacerbation of her bipolar symptoms, she was managed with
haloperidol as needed. She was discharged home on no
psychiatric medications, but with close monitoring from both
her psychiatrist and pediatrician.
DISCUSSION
DRESS syndrome usually presents within 8 weeks of
initiation of the causative medication. Aromatic
anticonvulsants (phenytoin, phenobarbital, carbamazepine) are
themost common cause ofDRESS, but avarietyof other drugs,
such as allopurinol, minocycline, dapsone, sulfasalazine, and
mexiletine, have also been associated with DRESS.
1 The
estimated occurrence of the syndrome is between 1 in 1,000
and 1 in 10,000 exposures to antiepileptic drugs.
2 There is a
10% mortality rate from DRESS, mostly due to liver damage
thought to be secondary to eosinophilic inﬁltration.
3 The
diagnostic criteria for DRESS syndrome include (a)
widespread cutaneous eruption; (b) fever; (c) systemic
involvement, including lymphadenopathy and/or 1 or more
internal organ involvements (for example, interstitial nephritis,
myocarditis, pericarditis, pneumonitis, hepatitis); and (d) 1 or
more biologic abnormalities (for example, eosinophilia
.1,500/mm
3, mononucleosis-like atypical lymphocytosis).
3–5
Before the diagnosis of DRESS can be made, other
diseases that may appear similar must be excluded. The
differential diagnoses include drug-induced lupus
erythematosus, hypereosinophilic syndrome, infectious
mononucleosis, Kawasaki disease, Stevens-Johnson syndrome,
toxic epidermal necrolysis, measles, pseudolymphoma,
immunoblastic lymphadenopathy, serum sickness-like reaction,
and staphylococcal toxic shock syndrome.
2 DRESS can be
particularly difﬁcult to distinguish from infectious etiologies,
and empiric antibiotics should be administered if clinically
appropriate.
6 Although no deﬁnitive laboratory test exists for
DRESS, a complete blood cell count can identify the
characteristic leukocytosis with eosinophilia, and liver-function
tests, renal function, and urinalysis can help identify internal
organ involvement.
3 Skin biopsy is not speciﬁc.
3
The exact pathophysiology of DRESS is not fully
understood. Several factors have been associated with the
development of DRESS, including a decrease in serum
immunoglobulin and circulating B cells.
7,8 It is unclear whether
these factors are preexisting or are induced by the medications
involved in DRESS. The long latency period between
medication administration and DRESS occurrence may
represent the time required for these effects to take place. In
addition, a connection between DRESS and human herpes virus
(HHV-6) reactivation has been suggested. However, because
reactivation of HHV-6 is not universal among DRESS syndrome
patients, they have been separated into a different clinical entity
known as drug-induced hypersensitivity syndrome.
9,10
The major consequences of DRESS include skin rash (that
may progress to exfoliative dermatitis), fever,
lymphadenopathy, and damage to viscera. The organ systems
most often affected are liver, kidneys, lungs, and heart (in the
form of pericarditis or myocarditis).
3 In approximately 50% of
patients, hepatitis develops, 10% develop nephritis, and 10%
develop pneumonitis.
6 Hepatic necrosis is the major contributor
to death, with mortality as high as 40% in these patients.
11
Discontinuation of the offending drug is the primary
treatment of DRESS. Antipyretics may also be used to control
fever. The use of systemic corticosteroids is controversial, as no
randomized, controlled clinical trials currently exist.
1,12 Steroid
treatment must be weighed carefully because steroids may
prolong wound healing, increase risks of infection, precipitate
gastrointestinal bleeding, and mask early signs of sepsis.
3 NAC
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drug detoxiﬁcation. It was used in the pediatric patient, given
her increasing liver-function tests and the NAC low-risk proﬁle.
However, currently insufﬁcient randomized controlled data
exist to support or oppose NAC use for DRESS syndrome.
13
The prognosis of DRESS is generally favorable if the
syndrome is recognized and the offending medication is
stopped before signiﬁcant visceral involvement has occurred.
5
The cutaneous manifestations may persist for several weeks,
and have been known to recur if systemic corticosteroids are
tapered too quickly or with re-exposure to the offending agent.
5
CONCLUSION
DRESS is a potentially life-threatening adverse drug
reaction that appears with diffuse skin rashes, fever, and
internal organ involvement. DRESS can lead to signiﬁcant
morbidity and mortality, but can often be treated by
discontinuing the offending agent and oral steroids. Emergency
physicians should consider DRESS in their differential
diagnosis of adult and pediatric patients with diffuse maculo-
papular rash and systemic symptoms.
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